Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bronchial basal cells (REGEND001) is an autologous stem cell therapy developed by Regend Therapeutics for the treatment of chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and bronchiectasis. The therapeutic process involves isolating basal cells from the patient's own bronchi via fiberoptic bronchoscopy or brushing, expanding these cells ex vivo, and then transplanting them back into the patient's pulmonary lesions. These cells serve as progenitor cells capable of regenerating bronchial and alveolar structures, thereby repairing damaged lung tissue and potentially restoring pulmonary function in patients with progressive respiratory failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bronchial basal cells.